Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Couverture accélérée du lambeau en cas de traumatisme grave des membres inférieurs (FLAP ATTACK)

13 novembre 2026 mis à jour par: Johns Hopkins University

Couverture accélérée des lambeaux par rapport au calendrier standard dans le traitement des blessures musculo-squelettiques graves des membres inférieurs

The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).

This is the vanguard and international part of the FLAP ATTACK trial.

Aperçu de l'étude

Description détaillée

Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.

The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.

The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.

Type d'étude

Interventionnel

Inscription (Estimé)

356

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Lily Mundy, MD
  • Numéro de téléphone: 410-706-2492
  • E-mail: LMundy3@jhu.edu

Lieux d'étude

    • Victoria
      • Melbourne, Victoria, Australie, 3004
        • Recrutement
        • The Alfred Hospital
        • Contact:
          • Lipi Shukla, MBBS, PhD
        • Chercheur principal:
          • Lipi Shukla, MBBS, PhD
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1N1
        • Recrutement
        • Vancouver General Hospital
        • Contact:
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L 4L2
        • Recrutement
        • Saint John Regional Hospital
        • Contact:
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Recrutement
        • Sunnybrook Health Sciences Centre
        • Contact:
      • Barcelona, Espagne, 08035
        • Recrutement
        • Vall d'Hebron University Hospital
        • Contact:
          • Jordi Tomás-Hernández, MD
        • Chercheur principal:
          • Antonio Bulla, MD, PhD
        • Chercheur principal:
          • Jordi Tomás-Hernández, MD
    • California
      • Sacramento, California, États-Unis, 95817
        • Recrutement
        • UC Davis Medical Center
        • Contact:
          • Ara A Salibian, MD
        • Chercheur principal:
          • Ara A Salibian, MD
        • Chercheur principal:
          • Augustine M Saiz, MD
    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Recrutement
        • The Johns Hopkins Hospital
        • Contact:
          • Lily R Mundy, MD
        • Chercheur principal:
          • Lily R Mundy, MD
      • Baltimore, Maryland, États-Unis, 21224
        • Recrutement
        • John Hopkins Bayview Medical Center
        • Contact:
          • Lily R Mundy, MD
        • Chercheur principal:
          • Lily R Mundy, MD
      • Baltimore, Maryland, États-Unis, 21201
        • Recrutement
        • R Adams Cowley Shock Trauma Center
        • Contact:
          • Mark J Gage, MD
        • Chercheur principal:
          • Mark J Gage, MD
      • Largo, Maryland, États-Unis, 20774
        • Recrutement
        • University of Maryland Capital Region Medical Center
        • Contact:
          • Todd Jaeblon, MD
        • Chercheur principal:
          • Todd Jaeblon, MD
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Recrutement
        • Oregon Health & Science University
        • Contact:
          • Graham J DeKeyser, MD
        • Chercheur principal:
          • Graham J DeKeyser, MD
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Recrutement
        • Vanderbilt University Medical Center
        • Contact:
          • Lauren M Tatman, MD
        • Chercheur principal:
          • Lauren M Tatman, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

The inclusion criteria are:

  1. Patients 18 years of age or older.
  2. Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
  3. Will have all planned flap surgeries performed by a participating surgeon or delegate.
  4. Able to be randomized within 48 hours of injury.

The exclusion criteria are:

  1. Site is unable to implement the accelerated flap protocol due to local logistics.
  2. Primary amputation anticipated prior to attempted flap for management of the injury.
  3. Critical limb ischemia that requires re-vascularization for limb perfusion.
  4. Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
  5. Burns at the musculoskeletal injury site.
  6. Incarceration.
  7. Expected injury survival of less than 12 months.
  8. Terminal illness with expected survival of less than 12 months.
  9. Currently enrolled in a trial that does not permit co-enrollment.
  10. Declined to provide informed consent.
  11. Unable to obtain informed consent due to language barriers.
  12. Unable to obtain informed consent because a legally authorized representative was unavailable.
  13. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
  14. Prior enrollment in the trial.
  15. Eligible patient or LAR was not approached within screening window (missed participant).
  16. Other reason to exclude the patient, as approved by the Principal Investigators.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Accelerated Flap Coverage

Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is with a goal of 72 hours from injury

Comparateur actif: Standard of Care Flap Timing

The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is the standard of care flap timing for the participating institution.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Clinical status
Délai: 6 months

Clinical status is a hierarchical composite of the following outcomes:

  1. All-cause mortality
  2. Amputation related to injury
  3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure)
  4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)
6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mortality
Délai: 6 months and 12 months

All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Amputation
Délai: 6 months and 12 months

Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Unplanned re-operation
Délai: 6 months and 12 months

Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse.

6 months and 12 months
Number of days in hospital
Délai: 6 months and 12 months

Days in an acute in-patient hospital (i.e., not rehab or nursing facility)

6 months and 12 months
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Délai: 6 months and 12 months

Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine".

6 months and 12 months
Quality of life as assessed by the Limb-Q
Délai: 6 months and 12 months

Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used.

6 months and 12 months
Clinical Status
Délai: 12 months

Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)

12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 novembre 2024

Achèvement primaire (Estimé)

1 août 2029

Achèvement de l'étude (Estimé)

1 février 2030

Dates d'inscription aux études

Première soumission

28 février 2024

Première soumission répondant aux critères de contrôle qualité

28 février 2024

Première publication (Réel)

5 mars 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • IRB00434587

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner